Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 18F-Flutemetamol Clear all
Completed No phase listed Observational Accepts healthy volunteers

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

NCT03466736
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
[18F]flutemetamol PET scan
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 12, 2026, 3:21 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Results available

Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels

NCT01165554
View directory record Official record
Conditions
Brain Fibrillarab Levels
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
55 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Results available

PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

NCT01053312
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 12, 2026, 3:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT07012993
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Healthy Volunteers
Interventions
18F-Florbetapir or 18F-Flutemetamol
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 1 Interventional

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

NCT05374564
View directory record Official record
Conditions
Cardiomyopathies, Primary
Interventions
(18F)Flutemetamol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 12, 2026, 3:21 AM EDT
Terminated Phase 3 Interventional Results available

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

NCT01092546
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 12, 2026, 3:21 AM EDT
Completed No phase listed Observational Results available

Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem

NCT02090855
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
55 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

NCT01607476
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
C11 PiB, F18 Flutametamol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 12, 2026, 3:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET

NCT01202994
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
18F-Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394
View directory record Official record
Conditions
Healthy
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 12, 2026, 3:21 AM EDT
Terminated Phase 2 Interventional Results available

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

NCT02317783
View directory record Official record
Conditions
Breast Cancer
Interventions
[18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 12, 2026, 3:21 AM EDT
Active, not recruiting Phase 2 Interventional

The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition

NCT03068442
View directory record Official record
Conditions
Cognitive Impairment, Carotid Artery Plaque, Inflammation
Interventions
Imaging with flutemetamol F 18 PET/CT
Drug
Lead sponsor
Scott Mcnally
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 12, 2026, 3:21 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

NCT05457998
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Diagnostic Test
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 12, 2026, 3:21 AM EDT
Completed Phase 3 Interventional Results available

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

NCT01028053
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Flutemetamol (18F) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Sep 12, 2026, 3:21 AM EDT